IL5 and asthma: In an animal model of asthma intratracheally delivered AP-1 decoy oligodeoxynucleotides attenuate eosinophilic airway inflammation, airway hyperresponsiveness, mucous cell hyperplasia, production of allergen-specific immunoglobulins, and synthesis of IL-4, IL-5, and IL-13 in the lung [111].